Clinical Trials
26 trialsNivolumab and Ipilimumab in Treating Patients With Rare Tumors
National Cancer Institute (NCI)
SUR-CAN
Centre Oscar Lambret
Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors
Memorial Sloan Kettering Cancer Center
Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma
Swiss Cancer Institute
A Phase II Trial of Cabozantinib With Patients With Refractory GCTs
Indiana University
PRIMETEST II - Clinical Stage II A/B Seminoma Treated With RA-RPLND
Heinrich-Heine University, Duesseldorf
GERMAN
N.N. Petrov National Medical Research Center of Oncology
RPLND-Seminoma
Western University, Canada
Therapy De-escalation in Seminoma Stage IIA/B
Swiss Cancer Institute
EDEN
Centre Leon Berard
Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors
Masonic Cancer Center, University of Minnesota
ARQ 197 for Participants With Relapsed or Refractory Germ Cell Tumors
Daiichi Sankyo
Car-PET
Barts & The London NHS Trust
Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors
Memorial Sloan Kettering Cancer Center
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Germ Cell Cancer
City of Hope Medical Center
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Novartis
SEMITEP
Gustave Roussy, Cancer Campus, Grand Paris
Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment
Memorial Sloan Kettering Cancer Center
Combination Chemotherapy and Pegfilgrastim in Treating Men With Metastatic Germ Cell Tumors
National Cancer Institute (NCI)
Ixabepilone in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors
National Cancer Institute (NCI)
Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer
National Cancer Institute (NCI)
Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer
National Cancer Institute (NCI)
Docetaxel in Treating Patients With Recurrent or Refractory Germ Cell Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell Transplantation
Fred Hutchinson Cancer Center
Immunotherapy in Treating Patients Who Are Undergoing Bone Marrow or Peripheral Stem Cell Transplantation
Fred Hutchinson Cancer Center
Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors
Fred Hutchinson Cancer Center